9920 Jefferson Blvd.
About ImmunityBio, Inc
ImmunityBio, Inc. is a late-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company’s immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.”
Stock Symbol: IBRX
3 articles with ImmunityBio, Inc
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022.
ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, announced today that the company will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17, 2022.
ImmunityBio is laying off 38 employees at its Dunkirk site in New York, Amneal will shutter a Long Island facility and Rigel culls 30 employees following wAIHA regulatory decision.